FDA approves new flu vaccine from GSK
submited by kickingbird at Oct, 9, 2006 14:41 PM from Sun-Sentinel
The Food and Drug Administration has approved FluLaval, a new seasonal influenza vaccine from GlaxoSmithKline Plc.
The FDA´s approval of FluLaval Thursday boosts the country´s expected flu vaccine supply for the 2006-07 influenza season to about 115 million doses.
FluLaval, which joins four other FDA-approved seasonal flu vaccines, is for use in people 18 and older, except those who are allergic to eggs and chicken proteins.
With a wholesale price of about $10 a dose, FluLaval was licensed under the FDA´s accelerated approval program.
GlaxoSmithKline, which also makes flu vaccine Fluarix, added FluLaval to its vaccine portfolio when it acquired ID Biomedical Corp., a Quebec, Canada, manufacturer, in December 2005. GlaxoSmithKline of Research Triangle Park, N.C., will distribute FluLaval.
The company expects to produce between 25 million to 27 million flu vaccine doses this season, Jennifer Armstrong, a company spokeswoman, said.
"We are expanding our seasonal flu vaccine offerings to include FluLaval, and we are investing heavily in new technologies and facilities to develop tomorrow´s vaccines to protect people from both seasonal and pandemic flu," said Chris Viehbacher, president of U.S. Pharmaceuticals, GlaxoSmithKline.
Other flu vaccine suppliers are: Sanofi Pasteur, which makes Fluzone; MedImmune Vaccines, which makes FluMist, a nasal spray vaccine; and Novartis Vaccine, which makes Fluvirin.
See Also:
Latest news in those days:
The FDA´s approval of FluLaval Thursday boosts the country´s expected flu vaccine supply for the 2006-07 influenza season to about 115 million doses.
FluLaval, which joins four other FDA-approved seasonal flu vaccines, is for use in people 18 and older, except those who are allergic to eggs and chicken proteins.
With a wholesale price of about $10 a dose, FluLaval was licensed under the FDA´s accelerated approval program.
GlaxoSmithKline, which also makes flu vaccine Fluarix, added FluLaval to its vaccine portfolio when it acquired ID Biomedical Corp., a Quebec, Canada, manufacturer, in December 2005. GlaxoSmithKline of Research Triangle Park, N.C., will distribute FluLaval.
The company expects to produce between 25 million to 27 million flu vaccine doses this season, Jennifer Armstrong, a company spokeswoman, said.
"We are expanding our seasonal flu vaccine offerings to include FluLaval, and we are investing heavily in new technologies and facilities to develop tomorrow´s vaccines to protect people from both seasonal and pandemic flu," said Chris Viehbacher, president of U.S. Pharmaceuticals, GlaxoSmithKline.
Other flu vaccine suppliers are: Sanofi Pasteur, which makes Fluzone; MedImmune Vaccines, which makes FluMist, a nasal spray vaccine; and Novartis Vaccine, which makes Fluvirin.
- US: Preliminary Testing Confirms Highly Pathogenic Avian Influenza in Queen Anne’s County in Maryland 12 hours ago
- China: Human cases of avian influenza A(H9N2) and (H10N3) reported in Hubei province, Chongqing Municipality and Guangxi Zhuang Autonomous Region 1 days ago
- US: Preliminary Testing Confirms Highly Pathogenic Avian Influenza in Caroline County in Maryland 2 days ago
- USDA Confirms Highly Pathogenic Avian Influenza in Backyard Non-Poultry Flock in Puerto Rico 2 days ago
- Scotland: Avian flu declaration near Kirriemuir, Angus on 10 January 2025 2 days ago
[Go Top] [Close Window]
